This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2007 by Singapore National Eye Centre.
Recruitment status was:  Active, not recruiting
Information provided by:
Singapore National Eye Centre Identifier:
First received: June 23, 2006
Last updated: September 25, 2007
Last verified: September 2007
To assess the use of Avastin for the management of serosanguinous maculopathy

Condition Intervention Phase
Choroidal Neovascularisation Polypoidal Choroidal Vasculopathy Drug: Bevacizumab (tradename: Avastin) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Off-Label Use of AVASTIN (BEVACIZUMAB)Intravitreal Injection For the Treatment of Serosanguinous Maculopathy

Resource links provided by NLM:

Further study details as provided by Singapore National Eye Centre:

Primary Outcome Measures:
  • Change from baseline in VA, i.e. gain or loss of 5 letters (1 line), 15 letters (3 lines) or 30 letters (6 lines)

Secondary Outcome Measures:
  • Change in OCT measured central retinal thickness
  • Correlation in change in central retinal thickness and change in VA

Estimated Enrollment: 50
Study Start Date: June 2006
Estimated Study Completion Date: May 2008
  Show Detailed Description


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. All subfoveal/juxtafoveal CNV and PCV (polypoidal choroidal vasculopathy) who are not eligible for other treatment options (compassionate use)
  2. CNV and PCV lesions which have failed PDT, conventional argon laser photocoagulation (salvage use)
  3. CNV and PCV lesions treatable with PDT, but cannot afford or refused

Exclusion Criteria:

  1. Patients with uncontrolled hypertension (systolic BP greater than 150mmHg or diastolic BP greater than 90mmHg
  2. History of thrombolic events such as myocardial infarction or cerebral vascular accident
  3. Renal abnormalities (as defined by established history of chronic renal disease or renal failure as well as patients requiring dialysis).
  4. Recent (as defined as the past 28 days) or planned (as defined as the next 3 months) surgery.
  5. Coagulation abnormalities, including anti-coagulant medication other than aspirin
  6. Patients with peptic ulcer disease
  7. Pregnant or lactating females
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00344617

Sponsors and Collaborators
Singapore National Eye Centre
Principal Investigator: Chong-Lye Ang, FRCOphth Singapore National Eye Centre
  More Information

Publications: Identifier: NCT00344617     History of Changes
Other Study ID Numbers: R452/01/2006
Study First Received: June 23, 2006
Last Updated: September 25, 2007

Keywords provided by Singapore National Eye Centre:
Choroidal neovascularisation
Polypoidal choroidal vasculopathy
Intravitreal injection

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Vascular Diseases
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Cardiovascular Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 22, 2017